| Literature DB >> 28443623 |
Debby M E I Hellebrekers1, Suzanne C E H Sallevelt1, Tom E J Theunissen1,2, Alexandra T M Hendrickx1, Ralph W Gottschalk1, Janneke G J Hoeijmakers3, Daphna D Habets1, Jörgen Bierau1, Kees G Schoonderwoerd4, Hubert J M Smeets1,2.
Abstract
In a 51-year-old patient of consanguineous parents with a severe neuromuscular phenotype of early-onset ataxia, myoclonia, dysarthria, muscle weakness and exercise intolerance, exome sequencing revealed a novel homozygous variant (c.-264_31delinsCTCACAAATGCTCA) in the mitochondrial FAD-transporter gene SLC25A32. Flavin adenine dinucleotide (FAD) is an essential co-factor for many mitochondrial enzymes and impaired mitochondrial FAD-transport was supported by a reduced oxidative phosphorylation complex II activity in the patient's muscle, decreased ATP production in fibroblasts, and a deficiency of mitochondrial FAD-dependent enzymes. Clinically, the patient showed improvement upon riboflavin treatment, which is a precursor of FAD. Our results confirm the recently reported case of SLC25A32 as a cause of riboflavin-responsive disease. Our patient showed a more severe clinical phenotype compared with the reported patient, corresponding with the (most likely) complete absence of the SLC25A32-encoding MFT (Mitochondrial Folate Transporter) protein.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28443623 PMCID: PMC5520074 DOI: 10.1038/ejhg.2017.62
Source DB: PubMed Journal: Eur J Hum Genet ISSN: 1018-4813 Impact factor: 4.246